141 related articles for article (PubMed ID: 19762712)
1. Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients?
Elsberger B; Tan BA; Mitchell TJ; Brown SB; Mallon EA; Tovey SM; Cooke TG; Brunton VG; Edwards J
Am J Pathol; 2009 Oct; 175(4):1389-97. PubMed ID: 19762712
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer.
Campbell EJ; McDuff E; Tatarov O; Tovey S; Brunton V; Cooke TG; Edwards J
Br J Cancer; 2008 Dec; 99(11):1769-74. PubMed ID: 19018258
[TBL] [Abstract][Full Text] [Related]
3. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
4. Is there an association with phosphorylation and dephosphorylation of Src kinase at tyrosine 530 and breast cancer patient disease-specific survival.
Elsberger B; Tan BA; Mallon EA; Brunton VG; Edwards J
Br J Cancer; 2010 Dec; 103(12):1831-4. PubMed ID: 21063412
[TBL] [Abstract][Full Text] [Related]
5. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
[TBL] [Abstract][Full Text] [Related]
7. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
Lindström LS; Karlsson E; Wilking UM; Johansson U; Hartman J; Lidbrink EK; Hatschek T; Skoog L; Bergh J
J Clin Oncol; 2012 Jul; 30(21):2601-8. PubMed ID: 22711854
[TBL] [Abstract][Full Text] [Related]
8. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
[TBL] [Abstract][Full Text] [Related]
9. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ
Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
[TBL] [Abstract][Full Text] [Related]
11. Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience.
Nwafor CC; Keshinro SO
Niger J Clin Pract; 2015; 18(4):553-8. PubMed ID: 25966732
[TBL] [Abstract][Full Text] [Related]
12. Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment.
Elsberger B; Paravasthu DM; Tovey SM; Edwards J
J Cancer Res Clin Oncol; 2012 Feb; 138(2):327-32. PubMed ID: 22134837
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival.
Onitilo AA; Engel JM; Greenlee RT; Mukesh BN
Clin Med Res; 2009 Jun; 7(1-2):4-13. PubMed ID: 19574486
[TBL] [Abstract][Full Text] [Related]
14. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
[TBL] [Abstract][Full Text] [Related]
15. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
[TBL] [Abstract][Full Text] [Related]
16. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer during follow-up and progression - A population based cohort on new cancers and changed biology.
Karlsson E; Appelgren J; Solterbeck A; Bergenheim M; Alvariza V; Bergh J
Eur J Cancer; 2014 Nov; 50(17):2916-24. PubMed ID: 25241230
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
19. HER2 expression in Brazilian patients with estrogen and progesterone receptor-negative breast carcinoma.
Ramalho S; Serra KP; Vassallo J; Soares FA; Pinto GA; Teixeira LC; da Cunha IW; Derchain SF; de Souza G
Acta Histochem; 2013 Mar; 115(2):120-7. PubMed ID: 22647460
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value and Influence of Receptor Conversion on Treatment Regimen in Metastatic Breast Cancer at the First Time of Recurrence.
Shen J; Xu L; Shi J; Zhao L; Shi S; Feng J; Han X; Shi Y; Wei Q; Wang D; Sun M; Mi X; Teng Y
Oncol Res Treat; 2020; 43(11):620-627. PubMed ID: 32966998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
